ArticleFrontiers in pharmacology2026
Ginsenoside Rb1 ameliorates stress urinary incontinence by upregulating SIRT1 to preserve mitochondrial homeostasis and MAM integrity.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stress urinary incontinence (SUI) is a prevalent pelvic floor disorder characterized by impaired connective tissue integrity. Oxidative stress-induced mitochondrial dysfunction has been implicated in pelvic floor degeneration. Ginsenoside Rb1 (Rb1), a bioactive component of ginseng, exhibits antioxidant properties; however, its therapeutic effects and underlying mechanisms in SUI remain unclear. Methods: A vaginal distension (VD)-induced mouse model of SUI and an H Results: Rb1 significantly improved bladder leak point pressure, preserved collagen organization, and reduced apoptosis in the anterior vaginal wall of VD mice. Rb1 alleviated oxidative stress by reducing ROS accumulation and restoring mitochondrial homeostasis. Mechanistically, Rb1 upregulated SIRT1 and enhanced mitochondrial biogenesis-associated signaling through the PGC-1α/NRF1/TFAM pathway, while promoting PINK1/Parkin-associated mitophagic signaling. Furthermore, Rb1 maintained mitochondria-associated membrane (MAM) integrity by regulating GRP75 acetylation, thereby reducing excessive ER-mitochondrial calcium transfer, mitochondrial calcium overload, and mtROS accumulation. SIRT1 inhibition or knockdown attenuated these protective effects. Conclusion: Ginsenoside Rb1 protects against SUI by promoting SIRT1-associated mitochondrial quality control and preserving MAM homeostasis through regulation of GRP75 acetylation. These findings identify the SIRT1-GRP75/MAM axis as a potential therapeutic target for preventing oxidative stress-induced pelvic floor tissue dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.